Clinical Effectiveness of Telmisartan in Patients with Metabolic Syndrome

Abstract

The research aimed at the investigation of possible effectiveness of telmisartan in patients with metabolic syndrome (MS). 75 patients with MS were investigated. They were randomized into 2 groups according to the prescribed treatment: I group – 40 patients who received statins, metformin and enalapril; II group – 35 patients for whom substitution of ACE inhibitor by telmisartan in daily dose of 40 mg was conducted. Effectiveness of the prescribed treatment was estimated in 3 months by level of blood pressure (BP), fasting glucose (FG) and blood lipid spectrum (total cholesterol (TC), triacylglycerols (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C)). Comparison of BP in patients of both groups revealed no statistical difference in 3 months of the treatment. Valid decreasing of FG level for 33% was detected in I group (5,8±0,11 comparing with 8,6±0,23 mmol/L, р<0,001). In II group statistically lower level of FG (4,6±0,18 comparing with 8,5±0,82 mmol/L, р<0,001) was observed while the absolute results of it tended to the correspondent figures of control group. Patients of II group were also characterized by more pronounced changes in blood lipid spectrum, such as decreasing of TC in 1,89 times (p<0,001), TG – by 12,5% (p<0,05), LDL-C – approximately twice (p<0,001), increasing of HDL-C in 2,66 times (p<0,001). Revealed changes are caused by fact that telmisartan is partial agonist of nuclear PPARγ- receptors, activation of which results in glucose-lowering and antiatherogenous effects. So, advisability of telmisartan in patients with MS opens new perspectives for its application in this category of patients